OBI Pharma, Inc. (Chinese: 台灣浩鼎生技股份有限公司) (TWSE: 4174) is a bio-pharmaceutical company, based in Nangang District, Taipei, Taiwan.
On 9 Feb 2007, its parent company Optimer Pharmaceuticals can buy/sell on Nasdaq Stock Exchange.
On 15 May 2012, OBI Pharma, Inc. was approved to become a public company in Taiwan.
On 23 Mar 2015, it can do transaction formally on OTC in Taiwan R.O.C.
The company mainly concentrates on the development of the research and development of cancer therapies and high quality drugs.